ALN-CFB

N/A

Report date: 2026/03/12 20:00:16
NME

Base Information

Drug NameALN-CFB
Drug Alias NameALN-CFB
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement factor B modulators
TargetsComplement factor B
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAnemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited KingdomSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAnemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A